NUK - logo
Institute of Oncology, Lj. (OILJ)
  • Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients
    Borštnar, Simona, 1967- ...
    Urokinase-type plasminogen activator (uPA), its inhibitors (PAI-1 and PAI-2), and its receptor (uPAR) play a key role in tumor invasion and metastasis. Thisstudy was designed to evaluate the ... prognostic impact of uPA, PAI-1, PAI-2,and uPAR and the combination of these factors in a group of 460 primary breast cancer patients. Concentrations of all 4 components of the uPA system were measured in tumor extracts using enzyme-linked immunosorbent assays (American Diagnostica, Inc, Greenwich, CT). After a median follow-up of 33 months, 18.5% of the patients had relapsed. The Cox proportional hazards modelwas applied for both univariate and multivariate analyses of disease-freesurvival (DFS). PAI-1 and PAI-2 were shown to provide independent prognostic information in breast cancer. Patients with either low levels of PAI-1 or high levels of PAI-2 were found to have better DFS (relative risk was2.08 and 1.78, respectively). The prognostic value could be even further improved by a combination of both inhibitors. Aside from the uPA inhibitors, only nodal status and hormonal receptor status retained independent prognosticvalue. The other 2 invasion markers, uPA and uPAR, showed no statistically significant impact on DFS. In our patients, who were mostly treated with adjuvant therapy, uPA was not found to be an independent prognostic marker for DFS; this could be a consequence of the predictive valueof uPA for response to adjuvant therapy and should be further investigated.
    Source: Clinical breast cancer. - ISSN 1526-8209 (Letn. 3, št. 2, 2002, str. 138-146)
    Type of material - article, component part
    Publish date - 2002
    Language - english
    COBISS.SI-ID - 19270105

source: Clinical breast cancer. - ISSN 1526-8209 (Letn. 3, št. 2, 2002, str. 138-146)

loading ...
loading ...
loading ...

Shelf entry